JPS6354692B2 - - Google Patents
Info
- Publication number
- JPS6354692B2 JPS6354692B2 JP54124726A JP12472679A JPS6354692B2 JP S6354692 B2 JPS6354692 B2 JP S6354692B2 JP 54124726 A JP54124726 A JP 54124726A JP 12472679 A JP12472679 A JP 12472679A JP S6354692 B2 JPS6354692 B2 JP S6354692B2
- Authority
- JP
- Japan
- Prior art keywords
- sporozoites
- chickens
- oocysts
- solution
- coccidiosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000287828 Gallus gallus Species 0.000 claims description 27
- 235000013330 chicken meat Nutrition 0.000 claims description 26
- 210000003046 sporozoite Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 208000003495 Coccidiosis Diseases 0.000 claims description 12
- 241000223932 Eimeria tenella Species 0.000 claims description 12
- 206010023076 Isosporiasis Diseases 0.000 claims description 12
- 229940124536 anticoccidial agent Drugs 0.000 claims description 6
- 239000003224 coccidiostatic agent Substances 0.000 claims description 6
- 210000003555 cloaca Anatomy 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000003250 oocyst Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/012—Coccidia antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は鶏コクシジウム症を免疫的に予防し得
る抗コクシジウム剤および該抗コクシジウム剤の
接種方法に関する。
鶏のコクシジウム症はある種の寄生性原虫の感
染により起きる伝染病で世界各国に広く分布して
いる。これに感染した動物は下痢、血便等の症状
を呈し、治療が遅れた場合または症状が重い場合
には斃死することも少なくない。そして斃死に至
らなくとも発育が阻害されるためにコクシジウム
症は養鶏家にとつて最も被害の大きい病気とされ
てきた。
従来、かかるコクシジウム症の予防としてワク
チンを含めて薬剤の経口投与が行われている。コ
クシジウム症のワクチンとはコクシジウム症を起
こし易い数種類のオーシストの混合液であり、こ
のものを鶏に経口投与するものである。しかし、
こうした薬剤の投与による予防法は、薬剤の耐性
獲得による効果の減退等の問題があり、また、ワ
クチンによる予防法は免疫持続期間が短く、免疫
期間中も完全に予防し得ないという欠点があつ
た。
本発明者らは前記問題を解決すべく研究を行つ
た結果、鶏コクシジウム症の原虫の一つであるア
イメリア・テネラのスポロゾイトを鶏の総排泄腔
より接種することによりコクシジウム症を予防し
得ることを見い出した。
本発明で云うスポロゾイトはアイメリア・テネ
ラのオーシストの発育環の一形態であり、生きて
いるものを指す。このスポロゾイトの調製法の例
を以下に示す。
アイメリア・テネラによるコクシジウム症に感
染した鶏の糞、盲腸管壁および盲腸内容等から分
離したアイメリア・テネラの成熟オーシストの皮
膜を磨砕し、スポロシストを得る。次いでこのス
ポロシストに鶏の胆汁とトリプシンを作用させス
ポロゾイトの脱嚢を行う。このようにして得られ
たものは主としてスポロゾイトを含み、他にオー
シストおよびスポロシストならびにオーシストお
よびスポロシストの皮膜をも含むものである。
次いで前記スポロゾイトを鶏に接種する。接種
の方法はリン酸緩衝液等の緩衝液にスポロゾイト
を懸濁せしめそしてこの溶液を鶏に接種する。接
種部位としては口腔、筋肉および総排泄腔が挙げ
られるが、特に総排泄腔に接種するのが好まし
い。総排泄腔接種の具体的方法としては、鶏の肛
門にスポロゾイトをたらすか、または総排泄腔に
注入する方法が挙げられる。スポロゾイトの接種
量は鶏1羽当り約500個以上がよい。
本発明に係る抗コクシジウム剤を用いれば副作
用を起こすことなくアイメリア・テネラによるコ
クシジウム症を殆ど完全に予防し得る。更に感染
防御効果も例えば初生雛に本発明の抗コクシジウ
ム剤を接種した場合、11週間以上と長く、非常に
有効なものである。
次に本発明の効果を示すために下記例を掲げ
る。
例 1
試験方法
0日令の鶏(ブロイラー専用種ハバード)10羽
の肛門に下記に示す試料をたらす。次いでこの鶏
に21日令において1羽当り20万個のアイメリア・
テネラの成熟オーシストを経口投与してコクシジ
ウム症に感染させる。対照は試料を接種せずに感
染のみ行つたものである。感染後8日目に盲腸病
変、糞中のオーシスト数、血便の有無および斃死
率について観察した。結果を表1に示す。なお評
価は以下の方法に従つて行つた。
試 料
本発明:アイメリア・テネラのスポロゾイト1万
個をPBS(−)溶液に懸濁せしめたもの。
比較例1:アイメリア・テネラのスポシスイト
5000個(スポロゾイトとして1万個)をPBS
(−)溶液に懸濁せしめたもの。
比較例2:アイメリア・テネラのオーシスト1250
個(スポロゾイトとして1万個)をPBS(−)
溶液に懸濁せしめたもの。
比較例3:本発明(1)の試料を60℃において30分間
加熱したもの。
比較例4:アイメリア・テネラのスポロゾイト1
万個を10%ホルマリン溶液に入れ30分間放置
し、次いでこの溶液を遠心分離し、沈澱を
PBS(−)溶液に懸濁せしめたもの。
試料に用いたオーシスト、スポロシストおよび
スポロゾイトの調製法は「J.Protozool.」第9巻
(2)第154〜161頁(1962)に記載されている方法に
基づいて以下のように行つた。
アイメリア・テネラの成熟オーシストを経口投
与した鶏の糞、盲腸管壁および盲腸内容物を集
め、3%重クロム酸カリウム溶液に浮遊せしめ、
そして28℃において2日間培養した。得られた成
熟オーシストを含む溶液を遠心分離(3000rpm、
10分間)し、そして沈澱を集める。次いでこの沈
澱を水で洗浄し且つ飽和食塩水を添加する。この
溶液を遠心分離(3000rpm、10分間)し、上澄を
とり、この上澄を水で希釈し、稀釈液を更に遠心
分離(1000rpm、3分間)し、そして沈澱を集め
る。この沈澱はほとんどオーシストのみよりなる
(比較例2で使用)。前記オーシストに水および5
%次亜塩素酸ナトリウム液を加え且つ15分間放置
した後、遠心分離(2000rpm、3分間)を行う。
得られた沈澱を水で洗浄し、次いでホモジナイザ
ーで磨砕する。この磨砕物はほとんどスポロシス
トよりなる(比較例1で使用)。このスポロシス
トに5%鶏胆汁および0.25%トリプシンPBS(−)
溶液を加え、そして40℃の温浴中でおよそ1.5時
間消化せしめる。得られた消化液を遠心分離して
沈澱を集め、そしてこの沈澱をPBS(−)溶液で
洗浄する。このものはほとんどスポロゾイトより
なる(本発明で使用)。
評価方法
盲腸病変:盲腸の萎縮および出血の程度、および
炎症滲出物の量の程度を示す。
:重度
:中等度
+:軽度
⊥:極軽度
−:なし
血便:程度は盲腸病変に準じる。
糞中のオーシスト数:糞1g中のオーシスト数を
表わす。
The present invention relates to an anti-coccidial agent capable of immunologically preventing chicken coccidiosis and a method for inoculating the anti-coccidial agent. Coccidiosis of chickens is an infectious disease caused by infection with a certain type of parasitic protozoan and is widely distributed around the world. Infected animals exhibit symptoms such as diarrhea and bloody stools, and often die if treatment is delayed or the symptoms are severe. Coccidiosis has been considered the most damaging disease for poultry farmers because it inhibits growth even if it does not lead to death. Conventionally, drugs including vaccines have been orally administered to prevent coccidiosis. A coccidiosis vaccine is a mixture of several types of oocysts that are susceptible to coccidiosis, and this is orally administered to chickens. but,
Prophylaxis methods using such drugs have problems such as a decline in effectiveness due to the acquisition of drug resistance, and prophylaxis methods using vaccines have the disadvantage that the duration of immunity is short and cannot provide complete protection even during the period of immunity. Ta. The present inventors conducted research to solve the above problem and found that coccidiosis can be prevented by inoculating sporozoites of Eimeria tenella, one of the protozoa of chicken coccidiosis, through the cloaca of chickens. I found out. The sporozoite referred to in the present invention is a form of the growth ring of the oocyst of Eimeria tenella, and refers to a living sporozoite. An example of the method for preparing this sporozoite is shown below. Sporocysts are obtained by grinding the membranes of mature oocysts of Eimeria tenella isolated from the feces, cecal wall, and cecal contents of chickens infected with coccidiosis caused by Eimeria tenella. Next, the sporocysts are treated with chicken bile and trypsin to excyst the sporozoites. The material thus obtained mainly contains sporozoites, but also contains oocysts and sporocysts, as well as oocysts and sporocyst membranes. The sporozoites are then inoculated into chickens. The inoculation method involves suspending sporozoites in a buffer such as phosphate buffer, and inoculating chickens with this solution. Inoculation sites include the oral cavity, muscle, and cloaca, and it is particularly preferable to inoculate the cloaca. Specific methods for cloacal inoculation include dropping sporozoites into the anus of chickens or injecting them into the cloaca. The amount of sporozoites inoculated should be about 500 or more per chicken. By using the anti-coccidial agent according to the present invention, coccidiosis caused by Eimeria tenella can be almost completely prevented without causing side effects. Furthermore, the infection-preventing effect is very effective, for example, when day-old chicks are inoculated with the anti-coccidial agent of the present invention for a long period of 11 weeks or more. Next, the following examples are given to demonstrate the effects of the present invention. Example 1 Test method: Drop the following sample into the anus of 10 0-day-old chickens (broiler breed Hubbard). The chickens were then given 200,000 Eimeria per bird at 21 days of age.
Mature oocysts of Tenella are administered orally to infect coccidiosis. As a control, only infection was performed without inoculating the sample. On the 8th day after infection, the rats were observed for cecal lesions, the number of oocysts in the feces, the presence or absence of bloody stool, and the mortality rate. The results are shown in Table 1. The evaluation was performed according to the following method. Sample Invention: 10,000 Eimeria tenella sporozoites suspended in a PBS(-) solution. Comparative example 1: Eimeria tenella spocysite
5000 pieces (10,000 pieces as sporozoites) on PBS
(-) Suspended in a solution. Comparative example 2: Eimeria tenella oocyst 1250
(10,000 sporozoites) in PBS (-)
suspended in a solution. Comparative Example 3: The sample of the present invention (1) was heated at 60°C for 30 minutes. Comparative example 4: Eimeria tenella sporozoite 1
10,000 pieces were placed in a 10% formalin solution and left for 30 minutes, then this solution was centrifuged to remove the precipitate.
Suspended in PBS(-) solution. The preparation method of oocysts, sporocysts, and sporozoites used as samples is described in "J.Protozool." Volume 9.
(2) The following procedure was carried out based on the method described on pages 154 to 161 (1962). The feces, cecal tube wall, and cecal contents of chickens to which mature oocysts of Eimeria tenella were orally administered were collected and suspended in a 3% potassium dichromate solution.
The cells were then cultured at 28°C for 2 days. The obtained solution containing mature oocysts was centrifuged (3000 rpm,
10 minutes) and collect the precipitate. The precipitate is then washed with water and saturated brine is added. The solution is centrifuged (3000 rpm, 10 minutes), the supernatant is removed, the supernatant is diluted with water, the diluted solution is further centrifuged (1000 rpm, 3 minutes), and the precipitate is collected. This precipitate consists almost exclusively of oocysts (used in Comparative Example 2). the oocysts with water and 5
% sodium hypochlorite solution and left to stand for 15 minutes, centrifugation (2000 rpm, 3 minutes) is performed.
The precipitate obtained is washed with water and then ground in a homogenizer. This ground material consists mostly of sporocysts (used in Comparative Example 1). This sporocyst was treated with 5% chicken bile and 0.25% trypsin in PBS (−).
Add the solution and allow to digest in a 40°C warm bath for approximately 1.5 hours. The obtained digestive fluid is centrifuged to collect a precipitate, and this precipitate is washed with a PBS(-) solution. This consists mostly of sporozoites (used in the present invention). Evaluation method Cecal lesions: Indicates the degree of cecal atrophy and bleeding, and the amount of inflammatory exudate. : Severe: Moderate +: Mild ⊥: Very mild -: None Bloody stool: The severity is similar to that of cecal lesions. Number of oocysts in feces: represents the number of oocysts in 1 g of feces.
【表】
例 2
試験方法
鶏(試験例1で用いたもの)10羽に下記に示す
試料を下記に示す方法で接種した。次いで試験例
1の方法に準じて感染および観察を行つた。対照
は試料を接種せず感染のみを行つたものである。
結果を表2に示す。評価の方法も例1に準じる。
試料および接種方法
本発明(1):鶏1羽当りスポロゾイト1万個を鶏の
肛門に接種する。
本発明(2):鶏1羽当りスポロゾイト1万個を鶏に
経口接種する。
本発明(3):鶏1羽当りスポロゾイト1万個を鶏の
胸筋に注射する。
比較例:鶏1羽当りオーシスト1250個を鶏に経口
接種する。
なお試料を用いたスポロゾイトおよびオーシス
トの調製法は例1の方法に準じる。[Table] Example 2 Test method Ten chickens (used in Test Example 1) were inoculated with the sample shown below using the method shown below. Next, infection and observation were performed according to the method of Test Example 1. As a control, only infection was performed without inoculating the sample.
The results are shown in Table 2. The evaluation method is also the same as in Example 1. Sample and inoculation method Present invention (1): 10,000 sporozoites per chicken are inoculated into the anus of the chicken. Present invention (2): Chickens are orally inoculated with 10,000 sporozoites per chicken. Present invention (3): 10,000 sporozoites per chicken are injected into the pectoral muscle of the chicken. Comparative example: Chickens are orally inoculated with 1250 oocysts per chicken. Note that the method for preparing sporozoites and oocysts using the sample is similar to the method in Example 1.
Claims (1)
分とする抗コクシジウム剤。 2 アイメリア・テネラのスポロゾイトを活性成
分とする抗コクシジウム剤を鶏の総排泄腔に接種
することを特徴とする鶏コクシジウム症の予防
法。[Claims] 1. An anti-coccidial agent containing Eimeria tenella sporozoites as an active ingredient. 2. A method for preventing coccidiosis in chickens, which comprises inoculating the cloaca of chickens with an anti-coccidial agent containing Eimeria tenella sporozoites as an active ingredient.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12472679A JPS5649323A (en) | 1979-09-29 | 1979-09-29 | Coccidiostat |
| US06/189,219 US4301148A (en) | 1979-09-29 | 1980-09-22 | Anticocoidial drug |
| FR8020785A FR2466250A1 (en) | 1979-09-29 | 1980-09-26 | ANTICOCCIDAL MEDICINAL PRODUCT, AND METHOD FOR VACCINATION OF POULTRY WITH THIS MEDICINAL PRODUCT |
| DE19803036458 DE3036458A1 (en) | 1979-09-29 | 1980-09-26 | ANTICOCCIDIENE MEDICINAL PRODUCT AND METHOD FOR PREVENTING THE POULTRY COCCIDIOSIS FROM USING THIS MEDICINAL PRODUCT |
| BR8006226A BR8006226A (en) | 1979-09-29 | 1980-09-26 | ANTICOCCIDIAL DRUG AND PREVENTIVE PROCESS OF COCCIDIOSIS IN BIRDS |
| GB8031204A GB2059769B (en) | 1979-09-29 | 1980-09-26 | Anticoccidial preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12472679A JPS5649323A (en) | 1979-09-29 | 1979-09-29 | Coccidiostat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5649323A JPS5649323A (en) | 1981-05-02 |
| JPS6354692B2 true JPS6354692B2 (en) | 1988-10-28 |
Family
ID=14892577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12472679A Granted JPS5649323A (en) | 1979-09-29 | 1979-09-29 | Coccidiostat |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4301148A (en) |
| JP (1) | JPS5649323A (en) |
| BR (1) | BR8006226A (en) |
| DE (1) | DE3036458A1 (en) |
| FR (1) | FR2466250A1 (en) |
| GB (1) | GB2059769B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57159719A (en) * | 1981-03-27 | 1982-10-01 | Nisshin Flour Milling Co Ltd | Coccidiostatic |
| CA1204057A (en) * | 1982-06-22 | 1986-05-06 | Eng-Hong Lee | Immunization against coccidiosis |
| EP0135073A3 (en) * | 1983-08-19 | 1987-05-27 | American Cyanamid Company | Antigens and monoclonal antibodies reactive against merozites of eimeria spp. |
| EP0135712A3 (en) * | 1983-08-19 | 1987-05-27 | American Cyanamid Company | Antigens and monoclonal antibodies reactive against sporozoites of eimeria spp. |
| US4710377A (en) * | 1983-08-19 | 1987-12-01 | American Cyanamid Company | Antigens and monoclonal antibodies reactive against sporozoites of Eimeria spp. |
| ATE157545T1 (en) | 1985-12-03 | 1997-09-15 | Dimminaco Ag Sa Ltd | ANTIGEN PROTEINS AND VACCINES CONTAINING THEM FOR PREVENTING COCCIDIOSIS |
| US4935007A (en) * | 1986-08-28 | 1990-06-19 | Eli Lilly And Company | Anticoccidial method |
| US5004607A (en) * | 1987-08-25 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Method of immunizing poultry |
| DE4001781C1 (en) * | 1990-01-23 | 1991-02-21 | Schott Glaswerke, 6500 Mainz, De | |
| JP2524360Y2 (en) * | 1992-09-17 | 1997-01-29 | 鈴野化成株式会社 | Cartridge type cosmetic container |
| US6500438B2 (en) | 1995-06-07 | 2002-12-31 | Pfizer Incorporated | In ovo vaccination against coccidiosis |
| WO1996040233A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | In ovo vaccination against coccidiosis |
| US6627205B2 (en) | 1997-12-01 | 2003-09-30 | Pfizer Incorporated | Ovo vaccination against coccidiosis |
| DE19828322A1 (en) * | 1998-06-25 | 1999-12-30 | Hoechst Roussel Vet Gmbh | New coccidiocide vaccine comprises inactivated, immunogenic sporocytes of pathogenic Eimeria species |
| US6984378B1 (en) * | 1999-02-26 | 2006-01-10 | Pfizer, Inc. | Method for the purification, recovery, and sporulation of cysts and oocysts |
| JP4104548B2 (en) * | 2001-08-30 | 2008-06-18 | エンブレクス,インコーポレイテッド | Improved method for producing zygote |
| US9050281B2 (en) * | 2008-05-29 | 2015-06-09 | Intervet Inc. | Coccidiosis vaccines |
| EP2355844A2 (en) * | 2008-11-13 | 2011-08-17 | Intervet International BV | Eimeria vaccine for turkeys |
| AU2019301657B2 (en) | 2018-07-10 | 2026-02-05 | Targan, Inc. | Systems and methods of preparing and delivering gels |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3147186A (en) * | 1961-04-03 | 1964-09-01 | Auburn Res Foundation | Stable coccidiosis immunization |
| FR2408351A1 (en) * | 1977-11-14 | 1979-06-08 | Unilever Nv | METHOD AND COMPOSITION FOR THE CONTROL AGAINST COCCIDIOSIS IN POULTRY |
-
1979
- 1979-09-29 JP JP12472679A patent/JPS5649323A/en active Granted
-
1980
- 1980-09-22 US US06/189,219 patent/US4301148A/en not_active Expired - Lifetime
- 1980-09-26 BR BR8006226A patent/BR8006226A/en unknown
- 1980-09-26 GB GB8031204A patent/GB2059769B/en not_active Expired
- 1980-09-26 DE DE19803036458 patent/DE3036458A1/en active Granted
- 1980-09-26 FR FR8020785A patent/FR2466250A1/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2059769A (en) | 1981-04-29 |
| JPS5649323A (en) | 1981-05-02 |
| DE3036458A1 (en) | 1981-04-16 |
| GB2059769B (en) | 1983-09-28 |
| FR2466250A1 (en) | 1981-04-10 |
| DE3036458C2 (en) | 1989-12-28 |
| US4301148A (en) | 1981-11-17 |
| BR8006226A (en) | 1981-04-07 |
| FR2466250B1 (en) | 1984-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6354692B2 (en) | ||
| EP0256878B1 (en) | Vaccines | |
| schmahl et al. | Treatment of fish parasites: 1. Praziquantel effective against Monogenea (Dactylogyrus vastator, Dactylogyrus extensus, Diplozoon paradoxum) | |
| EP0047662B1 (en) | Coccidiosis vaccines | |
| Shute | Latency and long-term relapses in benign tertian malaria | |
| US3147186A (en) | Stable coccidiosis immunization | |
| RO113716B1 (en) | METHOD OF VACCINATION OF HOUSEHOLDS AGAINST COCCIDIOUS | |
| KR20050098837A (en) | Coccidial vaccine and methods of making and using same | |
| WO1994016725A1 (en) | Live coccidiosis vaccine | |
| Basombrío et al. | Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice | |
| EP0687471A1 (en) | Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture | |
| EP0243548A1 (en) | A vaccine for immunization against coccidiosis | |
| Long et al. | Eimeria: immunisation of young chickens kept in litter pens | |
| Cuckler et al. | The effect of nicarbazin on the development of immunity to avian coccidia | |
| Biglake | Preliminary communication on the cultivation of Besnoitia besnoiti (Morotel, 1912) in tissue culture and embryonated eggs | |
| LUND | Immunizing action of a nonpathogenic strain of Histomonas against blackhead in turkeys | |
| Joyner et al. | Further observations on the genetic transfer of drug resistance in Eimeria maxima | |
| EP0258045A2 (en) | Method of improving the quality of animals | |
| Zimmermann et al. | Studies on fecal transmission of Trichinella spiralis | |
| MURAI | Morphological Studies on Bothriocephalus gowkongensis Yeh, 1955 and B. phoxini Molnár, 1968 (Cestoda» Pseudophyllidea) | |
| JPH0314004B2 (en) | ||
| Aitken et al. | Observations on the serological and dermal responses of turkeys to a single subcutaneous inoculation of inactivated Newcastle disease vaccine in mineral oil adjuvant | |
| JPH0343253B2 (en) | ||
| Pierson et al. | The effect of stress on the response of chickens to coccidiosis vaccination | |
| Lund et al. | Two Consecutive Transfers of Heterakis gallinarum: Effects on Caceal Worms and on Histomonads |